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Abstract
Objectives—High-dose, hypofractionated radiotherapy (HFRT) is sometimes used to treat 
malignancy in the head-and-neck (HN), both in the curative and palliative setting. Its safety and 
efficacy have been reported in small studies and are still controversial.
Materials and Methods—We retrospectively evaluated the outcomes and toxicities of HFRT, 
including ultra-high-dose fractionation schemes (≥8 Gray per fraction), for HN malignancies.
Results—A total of 62 sites of measurable gross disease in 48 patients were analyzed. The 
median follow-up was 54.3 months among five survivors and 6.0 months in the remaining patients. 
Median RT dose was 30 Gray in 5 fractions; 20/62 lesions (32%) received dose-per-fraction of ≥8 
Gray. Overall response rate at first follow-up was 79%. One-year local-progression free rate was 
50%. On multivariate analysis for locoregional control, dose-per-fraction ≥6 Gray was associated 
with control (p=0.04) and previous radiation was associated with inferior control (p= 0.04). 
Patients who achieved complete response to RT had longer survival than those who did not 
(p=0.01). Increased toxicity rates were not observed among patients treated with dose-per-fraction 
≥8 Gray; only re-irradiation increased toxicity rates.
Conclusion—Despite the poor prognostic features noted in this cohort of patients with HN 
malignancies, HFRT was associated with high response rates, good local control, and acceptable 
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toxicity. Sites that were treated with 6 Gray per fraction or higher and had not been previously 
irradiated had the best disease control. A prospective trial is warranted to further refine the use and 
indications of HFRT in this setting.
INTRODUCTION
Hypofractionated radiation therapy (HFRT) involves the use of high doses per fraction to 
achieve improved tumor control. A more desirable therapeutic ratio has been achieved for 
HFRT in recent years through the use of image-guided RT (IGRT), which allows improved 
certainty regarding daily treatment setup and dose delivered to organs at risk. IGRT has in 
turn facilitated the use of stereotactic body radiation therapy (SBRT), which allows delivery 
of highly conformal, high doses of radiotherapy to a clinical target. Preclinical data show 
that high-dose single-fraction RT operates via a unique mechanism involving injury of tumor 
endothelial cells that is distinct from conventionally fractionated RT and independent of 
tumor histologic subtype.[1] Clinical data show that HFRT improves local tumor control 
beyond that possible using conventional fractionation, for various scenarios including early-
stage lung cancer,[2, 3] radioresistant histologies such as melanoma and renal cell cancers,
[4–7] and oligometastatic disease.[8–12]
In recent years, a growing body of literature has reported on the safety and feasibility of 
HFRT for tumors of the head and neck (HN).[13–20] Most of these series include patients 
with recurrent, unresectable HN cancers who had been previously irradiated. These studies 
have found promising overall response rates up to 80% and 1-year local control rates in the 
range of 50%. Despite promising tumor control, severe toxicities have occurred in patients 
receiving HFRT for re-irradiation, including carotid blowout and hemorrhage.[14, 19] 
Carotid blowout in particular is a severe complication of high-dose radiation therapy in 
which there is physical rupture of the carotid artery and hemorrhage. This hemorrhage is 
potentially fatal if not addressed emergently. Several groups have reported on outcomes of 
HFRT used to treat a heterogeneous group of HN malignancies, including primary, 
recurrent, and metastatic tumors.[20, 21] These studies have also shown high response rates 
and 2-year local control rates of 30% to 40%, with limited toxicity in patients who had not 
been previously irradiated.
In our institution, HFRT is routinely offered to the most challenging HN disease 
presentations: those with “radioresistant” histologies (such as melanoma and renal cell 
carcinoma), cases of disease recurrence in a previously irradiated field, or bulky lesions for 
which rapid palliation is desired. After the year 2004, IGRT became available in our center. 
In recent years, SBRT has been routinely used for treatment of lesions with proximity to 
critical structures. As we have gained experience with HFRT in HN cancers, our dose 
prescribed per fraction has increased over time. In this study, we report on the outcomes and 
toxicity of HFRT for various malignancies with measurable gross disease in the HN. We also 
analyze the outcomes of patients who received an ultra-high dose (≥8 Gray per fraction) 
hypofractionated regimen to determine if these more intensive regimens were associated 
with improved outcomes.
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MATERIAL AND METHODS
We reviewed all cases of hypofractionated HN RT, which we defined as a dose of 5Gy or 
more per fraction, treated at our center from January 1997 to July 2014. We excluded 
patients who did not complete the prescribed course of radiotherapy and those who were 
treated to bone-only sites including the clivus. We therefore identified a total of 123 patients 
treated to 163 lesions in the HN. Within this group, we limited our analysis to patients with 
measurable gross disease, thereby excluding postoperative treatments following gross total 
resections, and at least one follow-up visit 30 days or more after completing HFRT.
Patients were offered HFRT to the HN tumor if they had one or both of the following 
features, as determined by the attending radiation oncologist: 1) radioresistant histology that 
would benefit from higher doses per fraction, 2) prior RT at the same site and not a 
candidate for salvage surgical resection or conventionally fractionated external beam RT, or 
3) no prior RT at the site, but cannot tolerate surgical resection or conventionally 
fractionated RT to curative doses. Patients were treated with either “definitive” or 
“palliative” intent. Patients treated “definitively” did not have evidence of metastatic disease 
and were technically considered “curable” despite being ineligible for surgical or other 
modalities of treatment. Patients treated with “palliative” intent had other metastatic or 
locoregional disease and were considered “incurable” even if this course of RT were to lead 
to a complete response of the treated lesion. Pretreatment evaluation consisted of a complete 
history and physical examination, comprehensive metabolic panel, complete blood count, 
computed tomography (CT) of the HN and chest, magnetic resonance imaging (MRI) as 
indicated, and whole body positron-emission tomography (PET) as indicated. Our 
institutional review board approved a waiver of written informed consent for this 
retrospective study.
Radiation treatment design
All patients underwent either CT or PET-CT simulation. CT images were obtained using 2–3 
mm slice thickness. Patients were immobilized in either a three-point or five-point 
thermoplastic face mask. Intravenous contrast was used for the simulation scan when 
indicated. Following CT-simulation, target volume was defined using available diagnostic 
CT, MRI, and/or PET images alongside the planning scan. For patients undergoing PET-CT 
simulation, the target volume was defined using the hypermetabolic tumor volume on the 
fused PET-CT scan. Treatments were targeted to local disease without elective nodal 
treatment. Any clinically or radiographically measurable gross disease was defined as the 
gross tumor volume (GTV). CTV was typically a 3–10 mm three-dimensional expansion on 
the GTV. The planning target volume (PTV) expansion on the CTV was dependent on the 
alignment technique, but was typically 2–3 mm for cases receiving IGRT with kV planar 
imaging or cone beam CT.
Dose was generally fractionated and delivered daily or every other day. Total dose and 
fractionation was selected by the attending radiation oncologist, based on field size, tumor 
location, prior radiation dose, and patient functional status. Treatment planning for 3D-
conformal and IMRT treatments was performed using our in-house treatment-planning 
system. Dose was prescribed to the isodose line best covering the PTV, while also protecting 
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normal tissues. The permitted normal tissue doses were defined by the attending radiation 
oncologist and were a function of fractionation scheme and any prior RT to the HN.
Response assessment
We determined objective response to HFRT using both clinical assessment and follow-up 
imaging. Patients were followed every 1–3 months on an outpatient basis. Follow-up 
evaluation consisted of an interval history and clinical examination focusing on the HN, 
often with fiberoptic endoscopy. Imaging included CT, MRI, and/or PET/CT routinely 
performed on a 3 to 6 month schedule. The follow-up interval was calculated from the last 
date of RT. Response was characterized using the RECIST criteria [22]: complete response 
(CR) if all tumor disappeared on follow-up evaluation, partial response (PR) if tumor 
exhibited at least >30% decrease in sum of diameters, stable disease (SD) if there was no 
change in tumor volume, and progression of disease (PD) if there was any increase in tumor 
size >20% and >5mm relative to pre-RT tumor volume. In certain cases progression was 
determined by the treating physician using primarily clinical examination.
Statistical analysis
We calculated in-field progression rate, locoregional progression-free rate (LRPF), overall 
survival (OS), and toxicity. All events were indexed to the final date of RT treatment. In-
field progression was defined as failure within the treatment field, and locoregional 
progression was defined as progression either in the treatment field or in a regional lymph 
node group or neighboring site. OS was calculated from the date of completion of the initial 
course of HFRT, to the date of death. Patients without events were censored at last follow-
up. Complications were scored per the Common Terminology Criteria for Adverse Events, 
version 4 (CTCAEv.4).[23] The Kaplan-Meier method was used for the generation of 
survival curves, and differences in survival curves were compared statistically with the log-
rank test. Univariate and multivariate analyses of potential prognostic factors were 
performed using the Cox proportional hazards model. The chi-square test was used to 
compare rates between subgroups of patients. All provided p values are two-sided with an α-
level of 0.05 considered significant. All statistical analysis was accomplished with the SPSS 
software package, version 22 (IBM, Armonk, NY).
RESULTS
Patient characteristics
Baseline characteristics for the initial cohort of 163 lesions in 123 patients, as well as for the 
analyzed group of 48 patients with 62 lesions, are available in Table 1. Predominant 
histologies of the 62 HN lesions were cutaneous melanoma (19%), mucosal melanoma 
(18%), squamous cell carcinoma (10%), and sarcomas (11%). Primary tumor site was nasal 
cavity in 18%, skin in 18%, and non-skin, metastatic cancer originating outside of the HN in 
23%. The HN had been previously irradiated in 24% of cases.
Treatment characteristics
Details of treatment, including sites and doses prescribed, are summarized in Table 2. 
Median age at HFRT was 70.2 years (range, 34–95). Patients were treated to a variety of HN 
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sites, with the neck (36%) being the most common. Treatment intent was definitive in 52%, 
and palliative in 48%. Median prescribed dose was 30 Gy (range, 18–48) in 5 fractions 
(range, 1–6). When dose was converted into equivalent dose in 2-Gy fractions (EQD2)[23] 
using an α/β ratio of 3 for radioresistant histologies (melanoma and renal cell carcinoma) 
and an α/β ratio of 10 for other histologies, median EQD2 was 50 Gy (range, 24–108).
Dose per fraction of 8 Gy or more was used in 20 (33%) cases. Three patients were treated 
with 5 Gy per fraction to a total dose of 25 Gy. The majority of patients (92%) were treated 
with intensity-modulated radiotherapy (IMRT) or 3D conformal RT. IGRT with on-board 2D 
or 3D techniques was used in 56% of patients, all treated in 2007 or later. All patients with 
melanoma or renal cell carcinoma (n=26) received HFRT with EQD2 ≥50 Gy. Patients with 
melanoma and renal cell carcinoma histologies were significantly more likely to receive an 
EQD2 ≥50 Gy than patients with other histologies (p ≤ 0.001).
Response to Treatment and Recurrences
Among the 48 patients with 62 treated lesions, median follow-up was 54.3 months among 
five surviving patients and 6.0 months in remaining patients. Response to RT is outlined in 
Table 3. At first follow-up visit after RT, 79% of target lesions demonstrated response, 16% 
had stable disease, and 3% had progression of disease. The two patients with progressive 
disease had anaplastic thyroid cancer metastatic to the orbit, and cutaneous squamous cell 
carcinoma metastatic to the parotid gland.
Among the 59 cases with either disease response or stability following HFRT, 10 cases 
remained progression-free, in both locoregional and distant sites. The most common site of 
relapse was distant-only in 34% of cases. Isolated locoregional failure in the HN without 
distant relapse occurred in 23 cases (39%), including 12 (19%) with isolated in-field 
recurrence without any regional or distant failure. In patients who recurred, median times to 
both isolated in-field progression and isolated LRP was 6.2 months (range, 0 – 33.9).
Overall Survival
Median OS for all 48 patients was 7.2 months (95% Confidence Interval [CI] 5.6 – 8.8 
months) [Figure 1a]. On log-rank testing, patients with complete response to treatment had 
far superior OS to those with less than complete response: 1-year OS was 100%, vs 34% in 
partial-response group (p=0.03) [Figure 1b]. Patients with metastatic tumors that had 
traveled to the head-and-neck also had inferior OS (median 6.5 vs 9.4 months, p= 0.05) 
[Figure 1c]. No difference in OS was observed based on dose per fraction ≥6 Gy or ≥8 Gy, 
age, chemotherapy use, EQD2, re-irradiation, or histology.
Five patients out of 48 were alive at last follow-up. In 43 patients who died, cause was head-
and-neck disease in 13 patients and due to other cause including systemic disease in 30 
cases.
Locoregional progression-free rate
LRPF rates were 70% (95% CI 57–83%) at 6-months, 43% (95% CI 27–59%) at 12-months, 
and 29% (95% CI 13–45%) at 2-years. On log-rank test, lesions with complete response 
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after HFRT had superior LRPF than patients with initial PR or less response (1-year rate 
67% if CR vs 42% if PR, p=0.009). Dose-per-fraction ≥6 Gy was associated with improved 
LRPF (1-year rate 46% vs 0%, p=0.01); dose-per-fraction ≥8 Gy was also significantly 
associated with improved LRPF (1-year rate 73% vs 34%, p=0.038) [Figures 2b and 2c]. 
Patients receiving re-irradiation had worse LRPF (median LRPF 12.7 months vs 6.2 months, 
p=0.017), which may be attributed to the lower dose per fraction and smaller radiation field 
treated in patients receiving re-irradiation. No significant differences in LRPF were observed 
based on tumor histology, receipt of chemotherapy, PTV volume, metastatic vs. primary HN 
tumor, or EQD2.
A subgroup analysis was performed on the 46 patients who had both 1) not received 
previous radiation, and 2) were treated with dose-per-fraction of 600cGy or higher. LRPF 
rates were 78% (95% CI 63–93%) at 6-months, 56% (95% CI 34–77%) at 12 months, and 
45% (95% CI 22 – 67%) at 2-years. Dose-per-fraction of 8Gy or higher was marginally 
associated with improved LRPF, although not statistically significant (1-year rate 83% vs 
45%, p=0.127). Other factors tested were not associated with differences in LRPF.
In-field control
Median in-field control was 11.9 months, with a 6-month estimate of 81% (95% CI 68- 
93%). Dose-per-fraction ≥6 Gy was associated with improved in-field control (12-month 
rate 54% vs 0%, p<0.001). No significant difference was seen among patients receiving 8Gy 
or higher (p=0.18). In-field control was not significantly worse in patients receiving re-
irradiation (12-month rate 60% vs 30%, p=0.10). No significant differences in in-field 
control were observed based on EQD2, chemotherapy, PTV volume, tumor histology, and 
metastatic vs. primary HN tumor.
A subgroup analysis was again performed on the 46 patients without re-irradiation, and with 
dose-per-fraction of 600cGy or higher. Median in-field control was 33.8 months, with a 6-
month estimate of 86% (95% CI 72 – 99%). No significant difference in in-field control was 
seen among patients based on dose 8Gy or higher (p=0.12), EQD2, chemotherapy, PTV 
volume, tumor histology, and metastatic vs primary HN tumor.
Cox Regression Analyses
Factors with p-value <0.10 on log-rank analysis for in-field control (Dose ≥6 Gy, re-
irradiation) and LRPF (Dose ≥6 Gy, dose ≥8 Gy, re-irradiation) were included in univariate 
and multivariate Cox regression analysis. For in-field control, only dose-per-fraction ≥6 Gy 
(HR, 0.1; p = 0.004; 95% CI, 0.02 – 0.42) remained significant. For LRPF, re-irradiation 
(HR, 2.2; p = 0.036; 95% CI, 1.1 – 4.5) and dose-per-fraction ≥6 Gy retained significance 
(HR, 0.27; p = 0.04; 95% CI, 0.08 – 0.95).
Toxicity
The highest acute toxicity that occurred was grade 1 in 37 cases (60%), grade 2 in 6%, and 
grade 3 in one case. No acute grade 4 or 5 toxicities occurred. Late grade 2 toxicities were 
recorded in 13% of cases, and 3% percent experienced late grade 3 complications, both 
involving retinopathies and vision loss. No carotid blowout or hemorrhage developed 
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following HFRT. On Chi-square test, sites that were re-irradiated were significantly more 
likely to experience grade ≥2 late toxicity (p <0.001) but not grade ≥2 acute toxicity. Dose 
≥8 Gy per fraction was not associated with an increase in grade ≥2 acute or late toxicities. 
No increased grade ≥2 late toxicity was seen in patients treated before routine use of on-
board imaging in 2004.
DISCUSSION
Locoregional control of malignancies in the head-and-neck is of paramount importance for 
quality of life and survival. Uncontrolled HN disease progression causes significant 
morbidity, justifying a more aggressive approach for recurrent disease or palliation of 
metastatic disease. In the setting of HN disease that cannot be surgically resected, the use of 
IGRT and SBRT has paved the way for radiotherapy dose-escalation, thereby improving the 
therapeutic ratio and locoregional disease control. Unfortunately, and especially for recurrent 
HN disease, RT comes with a risk of severe toxicities.[24–30] Hypofractionated IGRT with 
doses of 4–10 Gy per fraction has been used extensively in non-HN tumor sites and is 
considered a safe and effective treatment, particularly for radioresistant histologies and 
previously irradiated disease.[31, 32] Preclinical and clinical data show that higher doses per 
fraction overcome the traditional radioresistance of certain histologies.[4, 6, 7] HFRT 
represents an attractive treatment option for unresectable disease, because of an increase in 
local control over conventionally fractionated RT.[4] Another advantage of HFRT in the 
palliative setting is the shorter overall treatment time, which minimizes disruption of 
important systemic therapies. A small body of literature has described the use of HFRT for 
heterogeneous tumors in the HN, but more widespread application in the HN has yet to 
occur.
In our study, we find that patients who achieve CR to treatment have not only improved 
locoregional disease control, but also improved overall survival. Our finding underscores the 
great importance of local control for HN cancers. We also find that the dose-per-fraction of 
6Gy or higher with a median of 5 fractions is associated with improved outcomes compared 
to lower dose/fractionation schemes. In our study, patients who were re-irradiated had 
uniformly worse outcomes. These patients may benefit from a more aggressive 
multidisciplinary approach involving maximal resection, re-RT, and systemic therapy. For 
those who cannot undergo resection, a growing body of evidence shows that dose-escalated 
HFRT using SBRT to 40Gy or higher is associated with improved local control [15, 16, 21].
Our study also adds to the HN HFRT literature by including 20 patients treated with a dose 
per fraction of 8 Gy or above. On log-rank testing and univariate analysis, this dose range is 
associated with a trend to improved local control, although the analysis is limited by small 
patient numbers and low life-expectancy of this highly unfavorable patient population. With 
the rapid advances in SBRT planning and delivery, we can now safely treat gross tumor 
burden in the HN with doses that provide optimal local control. Our sample size is small and 
longer follow-up may reveal late toxicities; our results are nevertheless promising. We are in 
the process of generating a prospective trial of hypofractionated RT using SBRT for tumors 
in the HN, with the aims of evaluating toxicity, efficacy, and potentially broadening the 
indications for these treatments.
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Several series have found severe toxicities associated with SBRT for reirradiation of HN 
tumors. Cengiz et al[14] treated 46 patients with recurrent previously irradiated HN cancers 
to a median dose of 30 Gy in 5 fractions and found that 17% of patients had carotid blowout 
and 15% died of carotid bleeding. These patients had recurrent disease involving the carotid 
artery, which received full prescription dose. A Korean group treated 36 patients with 
previously irradiated HNC to doses of 18–40 Gy in 3–5 fractions; 3 developed necrosis 
associated with treatment.[13] A group from Kyoto[19] treated 21 recurrent HN cancers 
with CyberKnife SBRT to a median dose of 30 Gy in 3–8 fractions. At 24 months, OS was 
50%, but two patients died of pharyngeal hemorrhage at 5 and 28 months. The Henry Ford 
Hospital group[21] treated 37 HN lesions with fractionated SBRT of 36–48 Gy in 5–8 
fractions, and 18 lesions with single-fraction SBRT. They achieved 1-year tumor control 
rates of 61% to 83% and reported three grade 3 and four grade 4 toxicities, including fistulae 
that resulted from disease progression or regression. Unger et al[33] treated 65 patients with 
previously irradiated HN lesions to a median SBRT dose of 30 Gy in 5 fractions. Response 
was achieved in 81%. Severe toxicity including arterial bleeding, neuropathy, trismus, 
dysphagia, and necrosis developed in 11% of patients.
Other groups have achieved high response rates with acceptable toxicities. The University of 
Michigan published one of the earliest reports of HN SBRT[17] in which 13 patients were 
treated with SBRT to doses of 12–18 Gy in a single fraction or 30 Gy in 5–6 fractions. At 6-
months, nine patients showed response and no patients had acute or subacute radiation 
toxicity. The Pittsburgh experience[15] with CyberKnife for recurrent HN squamous cell 
carcinoma included 22 patients treated to a median dose of 24 Gy in 1–8 fractions. They 
report only two grade 2–3 acute toxicities and no late toxicities at a median follow-up of 19 
months. The same group reported results of SBRT reirradiation to the HN in 85 patients[16]: 
at 2 years, local control was 31% and OS was 16%. They found only four grade 3 acute 
toxicities, and no grade 3 or greater late toxicities. Comet et al[18] treated 43 previously 
irradiated HN lesions to 36 Gy in 6 fractions. At a median follow-up of almost 26 months, 
79% of patients achieved response and four patients had grade 3 toxicity. The authors note 
that they did not treat tumors invading more than one-third of the carotid artery.
Controversies do exist regarding the appropriateness of the linear-quadratic model in the 
setting of high-dose radiotherapy and radiosurgery.[35, 36] Studies of single-fraction 
radiosurgery show that cell killing at dose levels above 10 Gy occurs partially as a 
consequence of vascular endothelial damage, in addition to the classical model of single- 
and double-strand DNA breaks [1, 6]. The LQ model therefore underestimates the biological 
effects of a single-fraction dose that is “biologically equivalent” to a conventionally 
fractionated course, with equivalence calculated using the EQD2 model.[35] Several groups 
have proposed LQ models that better fit the observed in vitro cell kill from higher doses per 
fraction of radiosurgery[36], but these models are not yet widely accepted for clinical use. 
We currently do not have another reliably validated model to help us compare conventional 
fractionation and high-dose hypofractionation. We therefore used the LQ model and 
EQD-2Gy in order to facilitate comparison between the hypofractionated doses used in our 
study and a “biologically equivalent” conventionally fractionated course.
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Several potential sources of bias exist in this retrospective study. First, the decision to use 
HFRT versus conventional RT was chosen by the individual treating physician and not 
according to any formal criteria. We did find that patients with radioresistant histologies 
were more likely to receive a higher EQD2, a finding that is consistent with clinical practice. 
Another limitation of our study is the short survival and short median follow-up of patients 
who died, which may underestimate the number of late toxicities we encounter. However, 
with a median overall survival of 7.2 months, our length of follow-up is appropriate for this 
patient population with poor overall prognosis.
Our study shows that hypofractionated RT can be delivered safely and provides relatively 
high local control for challenging cancers in the HN and that a higher dose-per-fraction is 
associated with improved in-field control. More stringent selection criteria for HFRT, 
combined with more tailoring of dose and fractionation schedules to the individual lesion 
and patient, can likely reduce the development of late severe toxicities. A prospective dose-
escalation trial is warranted to find the optimal dose scheme in these patients.
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Highlights
1. Hypofractionated head and neck radiation therapy is controversial due to 
toxicity concerns.
2. 62 sites of measurable head-and-neck tumors were treated with high-dose 
radiation therapy.
3. Dose per fraction of 6Gy or greater had improved locoregional control.
4. Re-irradiated patients had worse disease control after hypofractionated 
radiation.
5. No increased toxicity was seen in patients treated with higher doses per 
fraction.
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Figure 1. 
Figure 1a. Overall Survival.
Teckie et al. Page 13
Oral Oncol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1b. Overall survival stratified by response to radiation therapy.
Figure 1c. Overall survival stratified by primary site of tumor (metastatic vs H&N).
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Figure 2. 
Figure 2a. Locoregional Progression-Free Survival.
Figure 2b. Locoregional progression-free rate, stratified by dose-per-fraction of 6Gy or 
higher.
Figure 2c. Locoregional progression-free rate, stratified by dose-per-fraction of 8Gy or 
higher.
Teckie et al. Page 16
Oral Oncol. Author manuscript; available in PMC 2017 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Teckie et al. Page 17
TABLE 1
Pretreatment clinical characteristics.
Characteristic Entire cohort (n=163), N (%) Intact tumors (n=62), N (%)
Age, years (median, range) 67.6 (18–95) 70.2 (34–95)
Primary tumor location
 Skin 68 (42) 11 (18)
 Nasal cavity 30 (18) 11 (18)
 Metastatic, non-skin cancer 20 (12) 14 (23)
 Oral cavity 9 (6) 2 (3)
 Paranasal sinus 7 (4) 4 (6)
 Neck 7 (4) 3 (5)
 Thyroid 6 (4) 6 (10)
 Parotid 4 (2) 4 (6)
 Nasopharynx 3 (2) 2 (3)
 Orbit 2 (1) 0 (0)
 Masticator space 2 (1) 2 (3)
 Oropharynx 1 (0.6) 0 (0)
 Hypopharynx 1 (0.6) 0 (0)
 Larynx 1 (0.6) 1 (2)
 Salivary Gland 1 (0.6) 1 (2)
 Unknown primary 1 (0.6) 1 (2)
Histologic diagnosis
 Cutaneous melanoma 73 (45) 12 (19)
 Mucosal melanoma 38 (23) 11 (18)
 Squamous cell carcinoma 11 (6) 6 (10)
 Sarcomas 10 (6) 7 (11)
 Carcinoma, NOS 7 (4) 6 (10)
 Thyroid 6 (4) 6 (10)
 Renal cell carcinoma 6 (4) 3 (5)
 Adenoid cystic 3 (2) 3 (5)
 Esthesioneuroblastoma 3 (2) 3 (5)
 Neuroendocrine 2 (1) 2 (3)
 Salivary gland carcinoma 2 (1) 2 (3)
 Non-small cell lung cancer 2 (1) 1 (2)
Prior head and neck RT 18 (11) 18 (24)
Abbreviation: RT, radiotherapy; NOS, not otherwise specified.
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TABLE 2
Details of head and neck sites treated with HFRT.
Characteristic Entire cohort (n=163), N (%) Intact tumors (n=62), N (%)
Treated Sites
 Neck 55 (34) 22 (36)
 Sinonasal 34 (21) 9 (15)
 Skin 29 (18) 10 (16)
 Parotid 16 (10) 6 (10)
 Orbit 7 (4) 6 (10)
 Mandible 5 (3) 3 (5)
 Ear 4 (2) 2 (3)
 Oral cavity 4 (2) 0 (0)
 Nasopharynx 3 (2) 2 (3)
 Oropharynx 3 (2) 0 (0)
 Hypopharynx 1 (0.6) 1 (2)
 Maxilla 1 (0.6) 0 (0)
 Thyroid 1 (0.6) 1 (2)
PTV Treated, cc, median (range) 112 (8 – 606cc)
Peri-radiotherapy chemotherapy
 None 32 (52)
 Yes, Before RT only 9 (15)
 Yes, Before, During, After RT 8 (13)
 Yes, After RT only 3 (5)
 Yes, Before and After RT only 9 (15)
 Months received, median (range) 6.1 (1.8 – 11.4)
RT Doses Received
 30Gy in 5 fx (6Gy per fx) 27 (44)
 36Gy in 6 fx (6Gy per fx) 11 (18)
 30Gy in 3 fx (10Gy per fx) 10 (16)
 24Gy in 3 fx (8Gy per fx) 4 (6)
 25Gy in 3 fx (5Gy per fx) 3 (5)
 27Gy in 3 fx (9Gy per fx) 2 (3)
 36Gy in 3 fx (12Gy per fx) 1 (2)
 48Gy in 4 fx (12Gy per fx) 1 (2)
 24Gy in 1 fx (24Gy per fx) 1 (2)
 20Gy in 2 fx (10Gy per fx) 1 (2)
 18Gy in 3 fx (6Gy per fx) 1 (2)
Abbreviations: HFRT, hypofractionated radiotherapy. RT, radiation therapy. Gy, Gray. Fx, fractions. PTV, planning target volumes.
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TABLE 3
Initial responses to head and neck HFRT (n=62).
Characteristic N (%)
Response
 Complete 6 (10)
 Partial 43 (69)
 Stable disease 10 (16)
 Progressive disease 2 (3)
 Unknown 1 (2)
Modality to determine response
 CT 10 (16)
 PET/CT 10 (16)
 MRI 16 (26)
 CT and MRI 2 (3)
 Clinical examination only 24 (39)
Abbreviations: CT, computed tomography. PET, postiron emission tomography. MRI, magnetic resonance imaging.
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TABLE 4
Sites of first recurrence in 59 treated lesions who initially had response or stable disease.
Location N (%)
 Local (in-field) only 12 (19)
 Regional only 9 (15)
 Distant only 21 (34)
 Local and regional 4 (6)
 Local and distant 1 (2)
 Regional and distant 3 (5)
 Local, regional, and distant 1 (2)
 No recurrence 11 (18)
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